For us, partnering is a key element in delivering meaningful therapies to patients with unmet medical needs. To complement our company's own R&D efforts, we collaborate with strategic partners to source new compounds, gain access to the latest technology platforms, and develop novel therapeutics for patients.

Our goal is to craft a pipeline that is a mix of both internal and externally-sourced assets that are in line with the company’s growth goals and strategically fit with both commercial and developmental strengths.

Independent from our therapeutic areas of focus, we are consciously agnostic of the source of assets that can enrich our global commercial and regional portfolio. The focus is first and foremost on the quality and potential benefit these assets can bring to patients. We consider all opportunities that have the potential to create value using innovative deal structures and creative alliances.

We are particularly interested in opportunities that will support our strategic business areas.

As an active player in Oncology, we strive to achieve a focused leadership position in selected indications. We are actively searching for and evaluating clinical-stage opportunities to strengthen our clinical pipeline. Priority is given to assets that are in development in our core indications, which include, but are not limited to SCCHN, CRC and urothelial cancers. For preclinical and early-stage clinical assets, we are actively searching for assets/technologies, which can support our Oncology R&D groups with a balanced portfolio of innovative targets and established approaches. Our three concept clusters within the research organization are:

• Cancer Cell Signaling
• Antibody-Drug Conjugates
• Tumor Immunology

From a modality perspective, we are largely focusing on biologics, small molecules including TPDs and ADCs. While we are open to explore clinical collaborations of our assets with novel modalities such as cell and gene therapies, mRNA therapeutics, cancer vaccines and oncolytic viruses, we would require clinical proof of concept as a starting point for deeper assessments.

In the Cancer Cell Signaling space, we are particularly interested in targeting oncogenic alterations and co-dependencies observed in molecularly defined tumors, as well as DNA Damage Response pathways. Our ADC experts are dedicated to develop  next-generation ADCs based on innovative protein, linker and payload technologies. Lastly, our Immuno-Oncology experts are exploring tumor antigen-targeted immune agonists, enhancers of tumor-specific T cell responses using highly selective small molecules, as well as immune agonist ADCs and immune cell-depleting ADCs.

Our focus in Tumor-Immunology is on actively stimulating the immune system, eliminating inhibitory mechanisms and targeting cancer stem cells. The Tumor Immunology strategy is based on four principles:

• Target “hot” tumors (high level of immune infiltration) and overcome resistance
• Target tumor myeloid and stromal factors
• Target “cold” tumors (low level of immune infiltration) to make them “hot”
• Identify novel resistance pathways

Our search space targeting “hot” tumors includes approaches on T-cell activation and co-stimulation, immune checkpoints beyond PD-1/PD-L1, or metabolic suppression. Profiling of tumor myeloid cells to find novel targets, new ways to inhibit myeloid suppressor cells (MDSC) and enhance macrophage and dendritic cell activity are also of interest to us. New routes to turn “cold” tumors into “hot” tumors may include combination approaches with Antibody-Drug-Conjugate or DNA-repair inhibitors, as well as immunocytokines and T-cell or NK cell re-directed therapies.

In addition to pre-clinical and clinical assets, we are interested in biomarker and technology platforms for the advancement of cancer (immuno)therapies.

Please contact the BD Oncology team for partnership proposals.

Our focus is the development of best-in-disease therapeutics in neurological and immunological diseases, with particular interest in:

• Movement disorders
• Neuromuscular disorders
• Acute CNS such as Acute Ischemic Stroke (AIS) or Traumatic Brain Injury (TBI)
• Peripheral autoimmune diseases such as Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN)
• Agents with the potential to induce immune tolerance/restore immune homeostasis.
  

Pre-PoC Focus
For pre-PoC assets, we are interested in the following MoAs:

• Inflammasome activation
• Autophagy, Lysosome pathway
• Cell Death Mechanisms
• Cellular Stress Response
• Mitochondrial Dysfunction
• Synaptic and axonal dysfunction
  

Post-PoC Focus
For post-PoC assets, we maintain a MoA-agnostic approach.

Modalities
We focus on advanced therapeutic modalities that have demonstrated proof-of-concept (PoC) and show strong differentiation potential. Key areas of interest include:

• Small molecules
• Biologics
• ADCs
• TPDs
• mRNA

For emerging modalities like cell and gene therapies, we focus on post-PoC opportunities with established clinical validation and robust CMC processes.
Please contact the GBD team for partnership proposals.

As a world leader in fertility treatment, we develop and provide innovative products, devices, and support services to assist infertile couples at every stage of the fertility treatment cycle, from follicular development to early pregnancy.

We actively search for and evaluate preclinical and clinical assets and technologies that align with our commitment to innovation and offer clear differentiation potential.

Our search scope includes novel therapies and drug delivery methods for medically assisted reproduction to enhance treatment outcomes, as well as adjacent women's health indications such as PCOS, Endometriosis and Ovarian Insufficiency, as well as Male Infertility. Furthermore, we are interested in clinical decision support systems for IVF treatment, and therapies aimed at improving oocyte quality and endometrial receptivity.

Our purpose is to bring better health to every single cardiometabolic and endocrine patient, helping them to live their life to its full potential. We must address chronic diseases such as diabetes, hypertension, growth hormone disorders or hypothyroidism, in view of their impact on health and society. Through our leading and affordable portfolio, ‘beyond the pill’ solutions and partnerships, we are helping to improve awareness, diagnosis, treatment and adherence of these diseases.

Every day, some 70 million patients across the globe use our trusted medicines like Glucophage^® and Glucovance^® (Diabetes); Concor^® (Cardiovascular); Euthyrox^® (Thyroids) or Saizen^® (Growth hormone deficiency). Our long-lasting and successful presence in Emerging Markets is based on strong local commercial and medical infrastructure as well as continued investment in our established brands.

We want to fuel additional growth via branded portfolio expansion and meet regional and global commercial needs. We strive to offer patients and physicians products, solutions and services that address unmet medical and patient needs in:

• Metabolism:
  • Type 2 Diabetes
  • Genetic obesity
  • Cong. Hyperinsulinism
  • Other rare metabolic conditions
    
• Cardiovascular Disease
  • Hypertension
  • Heart Failure
  • Lipid regulation
  • Coronary artery diseases
  • Hypertrophic cardiomyopathy
  • Other rare cardiovascular conditions
    

• Thyroids & Endocrinology:
  • Hypo/Hyperthyroidism
  • Hypoparathyroidism
  • Growth hormone regulation (GHD, acromegaly, others)
  • Cong. Adrenal hypoplasia
  • Other rare endocrine conditions

To support our Discovery and Development Technologies (DDTech) function as well as our Research and Development Units, we actively search for and evaluate novel technologies in two major areas:

Molecular, Technology and Screening Platforms

• Molecular platforms complementing our mAbs/binders/bispecific, ADC, and targeted protein degradation programs.
• New molecular approaches for targeted therapy via mAbs, ADCs, PROTACs/induced proximity, RNA targeting with small molecules.
• Innovative platforms to screen for SMEs (vs HTS & classical DELT).
• Ultra-high throughput clonal and functional screening of molecular binders (mAbs).
• Lab technologies, such as unique culture systems to assess drug effects in neuroscience and immunology as well as tumor-crosstalk and single-cell analytic approaches to investigate tumor heterogeneity and drug resistance.
• Next generation platforms to replace animal studies and provide improved translation (i.e., human-derived iPSC-based models/assays), and safety specific relevant Microphysiological Systems (MPS) models.
  

AI-augmented Technologies & Datasets

• Next-Gen approaches for AI powered drug discovery for small molecules and biological therapeutics.
• Data sets and AI/ML/LLM solutions for target identification and subsequent development of novel drug entities across modalities.
• Novel in silico prediction approaches connecting physical parameters for focused PK, immunization, protein-ligand, protein-protein insights.
• Access to large scale multi-omics datasets, HOR and RWD in the area of oncology and immuno-oncology.
• RWD sets and analytics for the improvement of clinical development e.g., clinical patient stratification, site selection.

We have dedicated ourselves to improving access to health in underserved populations with a focus on infectious diseases – especially malaria and schistosomiasis. Here we can contribute the competencies we have acquired from working at the interface of medicines, chemicals and diagnostics.

For most of these diseases, young children are the most vulnerable age group needing a suitable treatment. The goal is to develop innovative and integrated health solutions (drugs, diagnostics, medical devices, vector controls and digital health tools) for the most vulnerable populations in developing countries.

We are regularly reviewing our development candidate portfolio and are actively seeking partnerships for assets that we have strategically deprioritized. Such assets are typically in the late stage-preclinical / early-stage clinical development stage and fall in the areas of oncology, immuno-oncology, and immunology.

We are open to discuss partnering proposals with pharma and biotech organizations to license such assets, but are also open to build new companies around such assets with VC/PE investors.

As a global science-driven pharmaceutical company, we are dedicated to not only research, develop, and commercialize our therapeutics worldwide, but also to source innovation and collaborate on a global scale. As a BD team located in Singapore, Shanghai, and Tokyo we also source opportunities for the Asia Pacific markets from anywhere in the world. The BD Asia Pacific team is your first point of contact for any partnership proposals from or for the Asia Pacific region.

We are seeking to build our presence in New Therapeutic Areas focused on rare diseases in fields with high unmet need and limited competition where there is strong pricing potential. We seek post-proof-of-concept (POC) assets in these areas that have the potential to deliver transformative efficacy potential, and we prefer opportunities that include U.S. rights.

From a modality perspective, our focus is on small molecules, biologics, ADCs, TPDs, and mRNA, but we are open to all modalities. For new modalities such as cell and gene therapies, robust CMC will be of particular importance in addition to POC.

Please contact the Global Business Development team for partnership proposals.

Ensuring our alliances are supported by the right teams with the right resources is a priority for us. Our focus is on:

• Maximizing the value of the alliance for both partners, and reducing the risk of failure
• Resolving issues in advance in the best interest of the projects
• Providing a lead alliance governance structure
• Monitoring whether the legal framework of current alliances still reflect the initial objectives in light of the environmental changes
• New Opportunities: Identifying new opportunities with current partners